Scinai Immunotherapeutics Lt (SCNI) Quarterly Institutional 13F Update (Q2 2026)

SCNI ranks #9853 out of 37505 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

SCNI is a disclosed holding of Ken Griffin (Citadel Advisors LLC), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

11 institutions disclose a position in SCNI, but none treat it as a major bet — even Citadel Advisors LLC, its most concentrated holder, allocates just 0.0% of its own portfolio to it.

XTX Topco Ltd has trimmed its SCNI position for two straight quarters, cutting it by $15.2K while still holding $4.2K.

SCNI reported a net loss of $5.8M in its latest fiscal year.

• Not yet profitable — net loss of $5.8M in the latest fiscal year
• Net income improved year over year, from -$8.2M to -$5.8M
• Operating cash flow was negative, using $7.3M in cash
• Current ratio of 6.15x — enough short-term assets to cover short-term liabilities
• Total liabilities currently exceed total assets (negative shareholder equity)